We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Leonard Marks MD

Leonard S. Marks MD

deKernion Endowed Chair in Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California

Dr. Marks is Professor of Urology at the David Geffen School of Medicine at UCLA. He was graduated from the University of Texas, where he received the M.D. with AOA honors and Masters of Arts (Physiology) degrees in 1969. He served an internship and surgical residency at UCLA/Harbor General Hospital. For 2 years after that, he served on active duty as Lt. Cdr. in the U.S. Public Health Service. He was named a Post-Doctoral Research Scholar at UCLA School of Medicine in 1973-4. He completed his urology residency at UCLA and was Lecturer in Urology there in 1978, following which he entered private practice in Los Angeles.   He re-joined the UCLA faculty full-time in 2009.

While in practice, Dr. Marks founded a non-profit research organization, Urological Sciences Research Foundation, a 501c3 corporation, to further his academic interests. He became an original AFUD scholar in 1992 for work relating serum PSA levels to prostate histology. He received a Prostate Cancer Foundation (PCF) research award in 2000 for cross-cultural studies of prostate cancer. An early advocate of multimedia in urology, he served as Website Editor of Urology (The Gold Journal) from 1998-2010.  For his work in the scientific evaluation of alternative medicines,  he was appointed to committees of the American Urological Association, the National Institutes of Health (NCCCAM and NIDDK), and the National Academy of Sciences. 

He has for the past 3 years been Principle Investigator of an R01 Award from the National Cancer Institute, devoted to targeted prostate biopsy. He has authored more than 120 scientific publications.